Brand Reference: Depo-Testosterone
| Metric | Verified Benchmark | Source |
|---|---|---|
| Testosterone Cypionate (17-Beta-Cyclopentylpropionate) RxNorm Concept ID | 10379 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.1200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $98.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $99.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $42.00 / mo | 48 Zero-PHI Verified Patient Logs |
8-carbon cyclopentylpropionate ester depot cleaved slowly in systemic circulation to bioidentical testosterone, binding cytosolic androgen receptors in skeletal myocytes, osteoblasts, and CNS nuclei while undergoing 5-alpha reduction to DHT and CYP19A1 aromatization to estradiol.
Classified under Esterified Parenteral Androgen Receptor Agonist (Rx), Testosterone Cypionate (17-Beta-Cyclopentylpropionate) exhibits a $56.00/month gap between standard U.S. retail cash counters ($98.00) and verified direct-to-patient routing ($42.00) anchored to $3.1200 CMS unit cost.
Pharmacokinetic profiling of Testosterone Cypionate (17-Beta-Cyclopentylpropionate) demonstrates an elimination half-life of ~8 days depot release with 100% IM or shallow SC cottonseed/grapeseed carrier systemic bioavailability; clearance proceeds via hepatic 17-ketosteroid conjugation via ugt2b17 and peripheral 5-alpha-reductase/aromatase, reaching clinical onset within 24–72 hours serum peak; 5 weeks steady-state hematologic equilibrium.
Titration schedules for Testosterone Cypionate (17-Beta-Cyclopentylpropionate) (50 mg SC/IM twice weekly (100 mg/wk) → 70 mg SC/IM twice weekly (140 mg/wk) → 100 mg IM every 7 days) require excluding carcinoma of the male breast or prostate; baseline hematocrit > 52%; untreated severe obstructive sleep apnea; active fertility attempt without hcg/serm; real-world patient logs highlight testicular volume decrease (29% of reports), hematocrit +3.5% (26% of reports), truncal sebaceous acne (15% of reports) alongside a 94.20% Worth-It consensus.
Across 48 verified cash-pay logs, Testosterone Cypionate (17-Beta-Cyclopentylpropionate) achieves a 94.20% Worth-It rating with out-of-pocket spend averaging $42.00/mo versus $98.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to TeleMed at 50 mg SC/IM twice weekly (100 mg/wk) for Testosterone Cypionate (17-Beta-Cyclopentylpropionate); monthly out-of-pocket dropped to $36.96 compared with $98.00 retail.
Completed 10 weeks on Testosterone Cypionate (17-Beta-Cyclopentylpropionate) (70 mg SC/IM twice weekly (140 mg/wk)). Zero notable side effects on steady dosing.
Consistent biomarker response on 100 mg IM every 7 days Testosterone Cypionate (17-Beta-Cyclopentylpropionate) sourced via Cash Clinic ($48.72/mo cash pay without insurance prior authorization).